B7-H1 protein vaccine induces protective and therapeutic antitumor responses in SP2/0 myeloma-bearing mice

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2442-2448

  Zhang, Cun ^a   Wang, Weihua ^a   Qin, Xin ^a   Xu, Yujin ^a   Huang, Tonglie ^a   Hao, Qiang ^a   Li, Weina ^a   Wu, Shouzhen ^a   Zhang, Yingqi ^a  

^a State Key Laboratory of Cancer Biology   (China)

Author keywords

B7 H1; CD4 + Foxp3+ regulatory T cells; Immune evasion; Tetanus toxoid T helper epitope; Vaccine

Indexed keywords

CD4 ANTIGEN; EPITOPE; GAMMA INTERFERON; PROGRAMMED DEATH 1 LIGAND 1; TETANUS TOXOID; TRANSCRIPTION FACTOR FOXP3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; LYMPHOCYTE COUNT; MOUSE; MYELOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES; ANTIGENS, CD274; APOPTOSIS; CANCER VACCINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACROPHAGES; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 84885037980     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2686     Document Type: Article

References (26)

1. Dong H, Zhu G, Tamada K and Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5: 1365-1369, 1999.
2. Dong H, Strome SE, Salomao DR, et al: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800, 2002.
3. Hansen JD, Du Pasquier L, Lefranc MP, Lopez V, Benmansour A and Boudinot P: The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective. Mol Immunol 46: 457-472, 2009.
4. Freeman GJ, Long AJ, Iwai Y, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-1034, 2000.
5. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H and Nishimura M: B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 10: 5094-5100, 2004.
6. Wintterle S, Schreiner B, Mitsdoerffer M, et al: Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 63: 7462-7467, 2003.
7. Ghebeh H, Mohammed S, Al-Omair A, et al: The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8: 190-198, 2006.
8. Hasan A, Ghebeh H, Lehe C, Ahmad R and Dermime S: Therapeutic targeting of B7-H1 in breast cancer. Expert Opin Ther Targets 15: 1211-1225, 2011.
9. Thompson RH, Kuntz SM, Leibovich BC, et al: Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66: 3381-3385, 2006.
10. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T and Minato N: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99: 12293-12297, 2002.
11. Wilcox RA, Feldman AL, Wada DA, et al: B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 114: 2149-2158, 2009.
12. Selenko-Gebauer N, Majdic O, Szekeres A, et al: B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 170: 3637-3644, 2003.
13. Fukaya T, Takagi H, Sato Y, et al: Crucial roles of B7-H1 and B7-DC expressed on mesenteric lymph node dendritic cells in the generation of antigen-specific CD4+Foxp3+ regulatory T cells in the establishment of oral tolerance. Blood 116: 2266-2276, 2010.
14. Luo X, Tarbell KV, Yang H, et al: Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 104: 2821-2826, 2007.
15. Yamazaki S, Bonito AJ, Spisek R, Dhodapkar M, Inaba K and Steinman RM: Dendritic cells are specialized accessory cells along with TGF- for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3 precursors. Blood 110: 4293-4302, 2007.
16. Zhang C, Wu S, Xue X, et al: Antitumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV. Cytotherapy 10: 711-719, 2008.
17. Dalum I, Jensen MR, Hindersson P, Elsner HI and Mouritsen S: Breaking of B cell tolerance toward a highly conserved self protein. J Immunol 157: 4796-4804, 1996.
18. Dalum I, Butler DM, Jensen MR, et al: Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 17: 666-669, 1999.
19. Xue X, Feng G, Li M, et al: Amelioration of experimental autoimmune encephalomyelitis by BLyS autovaccine. Vaccine 26: 2873-2881, 2008.
20. Renard V, Sonderbye L, Ebbehoj K, et al: HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. J Immunol 171: 1588-1595, 2003.
21. Valmori D, Pessi A, Bianchi E and Corradin G: Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J Immunol 149: 717-721, 1992.
22. Yu Z, Healy F, Valmori D, Escobar P, Corradin G and Mach JP: Peptide-antibody conjugates for tumour therapy: a MHC-class-II-restricted tetanus toxin peptide coupled to an anti-Ig light chain antibody can induce cytotoxic lysis of a human B-cell lymphoma by specific CD4 T cells. Int J Cancer 56: 244-248, 1994.
23. Suh WK, Wang S, Duncan GS, et al: Generation and characterization of B7-H4/B7S1/B7x-deficient mice. Mol Cell Biol 26: 6403-6411, 2006.
24. Gallina G, Dolcetti L, Serafini P, et al: Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 116: 2777-2790, 2006.
25. Zang X and Allison JP: The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 13: 5271-5279, 2007.
26. Blank C, Kuball J, Voelkl S, et al: Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 119: 317-327, 2006.